



GEORGIA DEPARTMENT  
OF COMMUNITY HEALTH

## Georgia Department of Community Health

# DRUG UTILIZATION REVIEW BOARD MEETING

Department of Community Health  
2 Peachtree Street – **5<sup>th</sup> Floor Board Room**  
Atlanta, Georgia 30303

**May 7, 2019**

*This page intentionally left blank*



## DRUG UTILIZATION REVIEW BOARD MEETING

### AGENDA

*2 Peachtree Street - 5<sup>th</sup> Floor DCH Board Room*

*Atlanta, Georgia 30303*

**Tuesday, May 7, 2019**

**10:00 a.m. to 3:00 p.m.**

<b>CALL TO ORDER</b>	<i>Burton L. Lesnick, M.D., FAAP, Chair</i>
<b>MINUTES FROM PREVIOUS MEETING</b>	<i>Chair</i>
<b>EXTERNAL COMMENTS SESSION</b>	<i>Chair</i>
<b>CLINICAL REVIEWS</b>	<i>Afzal Mistry, PharmD, NorthStar Chad Nicholson, PharmD, NorthStar Emily Baker, PharmD, BCPS, NorthStar</i>
➤ <b>New Drugs</b>	
● Ajovy	
● Delstrigo	
● Doptelet	
● Emgality	
● Ilumya	
● Jivi	
● Mulpleta	
● Olumiant	
● Pifeltro	
● Xofluza	
<b>ADJOURNMENT OF OPEN SESSION</b>	<i>Chair</i>
<b>EXECUTIVE SESSION</b>	<i>Nina Bandali, PharmD, Pharmacist Account Manager, Magellan Rx Management</i>
<b>RECONVENING OF OPEN SESSION</b>	<i>Chair</i>
<b>BOARD'S RECOMMENDATIONS AND VOTES</b>	<i>Chair</i>
<b>FUTURE AGENDA ITEMS</b>	<i>Chair</i>
<b>ADJOURNMENT OF MEETING</b>	<i>Chair</i>

*This page intentionally left blank*

**Department of Community Health  
Drug Utilization Review Board (DURB)  
MINUTES  
Tuesday, March 5, 2019**

**MEMBERS PRESENT**

Burton L. Lesnick, M.D., FAAP, Chair  
M. Celeste Fowler, Pharm.D., Vice-Chair  
Mia Avery, Pharm.D.  
Alton Condra III, R.Ph.  
Gurinder Doad, M.D.  
Robyn Lorys, Pharm.D.  
J. Russell May, Pharm.D.  
Osgood (Drew) A. Miller, R.Ph.  
Matthew Perri, R.Ph., Ph.D.  
Brent L. Rollins, R.Ph., Ph.D.  
Danny A. Toth, R.Ph.

**MEMBERS ABSENT**

Doug Collins, M.D.  
Rod M. Duraski, M.D., FACP, MBA  
Glenda Wrenn Gordon, M.D.

**Staff**

Peter D'Alba, R.Ph., Pharmacy Director, Pharmacy Services  
Gilletta Gray, R.Ph., Clinical Manager, Pharmacy Services  
Maria Lucas, Pharmacy Program Specialist, Pharmacy Services  
Rebecca Morrison, Pharmacy Program Specialist, Pharmacy Services  
Rose Marie Duncan, MBA, Operations Analyst-Drug Rebate Program, Pharmacy Services  
Lori Garner, MHS, MBA, R.Ph., Pharmacist, SHBP

**NorthStar HealthCare Consulting**

Emily Baker, Pharm.D., BCPS, MHA, MBA, President  
Afzal "Fez" Mistry, Pharm.D., Clinical Programs Director  
Chad Nicholson, Pharm.D., Clinical Pharmacist

**OptumRx**

Kelly Coleman, Account Manager, Government Markets, Relations & Reform

**Magellan Rx Management**

Nina Bandali, Pharm.D., Pharmacist Account Manager

**Care Management Organizations**

Turkesia Robertson-Jones, Pharm.D., CareSource  
Charles Kim, Pharm.D., PeachState

**Call to Order**

The Drug Utilization Review Board (DURB/DUR Board/Board) held its first meeting for the calendar year on March 5, 2019. The Chair, Burton L. Lesnick, M.D., FAAP, called the meeting to order at 10:03am.

**Minutes from the Previous Meeting**

Chair Lesnick asked for corrections or changes to the minutes from the November 6, 2018 meeting. A motion was made (Danny A. Toth, R.Ph.), seconded (J. Russell May, Pharm.D.), and carried to approve the minutes as written.

**External Comments Session**

There were no external comments.

**New Drug Reviews**

Clinical information for the following new drugs, in the market six months or more, was presented for discussion and recommendations. The complete detailed drug summary is in the New Drugs for Review section of the DUR Board binder.

Therapeutic Class	Drugs	Presenter
<b>Immunomodulators, Asthma</b>	<i>Fasenra</i>	Chad Nicholson, Pharm.D.
<b>Potassium Binders</b>	<i>Lokelma</i>	Afzal “Fez” Mistry, Pharm.D.
<b>Opiate Dependence Treatments</b>	<i>Lucemyra</i>	Afzal “Fez” Mistry, Pharm.D.
<b>Uterine Disorder Treatments</b>	<i>Orilissa</i>	Chad Nicholson, Pharm.D.
<b>Antibiotics, Vaginal</b>	<i>Solosec</i>	Afzal “Fez” Mistry, Pharm.D.
<b>Aminoglycosides</b>	<i>Zemdri</i>	Chad Nicholson, Pharm.D.

The Board discussed the drug information, provided comments, and raised questions on the following:

- Lokelma – loop or thiazide diuretics typically used in mild to moderate kidney disease; use in peritoneal dialysis-may be pivotal if other treatment not effective (correcting fluids, diuretics, avoiding meds/foods that increase potassium).
- Lucemyra-level of evidence of clonidine causing more hypotension; don’t underestimate the hypotension caused by this drug; doesn’t address all withdrawal symptoms; role in outpatient-seen in inpatient, may be used in MAT clinics, used for mitigation of withdrawal symptoms short term, don’t see role in MAT clinic if abrupt discontinuation and withdrawal symptoms but possibly covering latter half of therapy as outpatient; look at outcome of methadone to non-preferred status; patients should be monitored; prisons and drug-free residential programs-may fill a niche; primary evidence citing hypotension

**Department of Community Health  
Drug Utilization Review Board (DURB)  
MINUTES**

**Tuesday, March 5, 2019**

difference between clonidine and Lucemyra comes from National Institute of Healthcare and Excellence, could be slight difference in receptor activity.

- Solosec-step of metronidazole would be because of non-compliance, not failure, safety profile similar; relapse rate high; if failure, try different drug (e.g. clindamycin); main benefit-administered once compared to seven days of metronidazole; may be a better choice if compliance an issue; common prevalence; chronic metronidazole use and male circumcision shown to reduce recurrence rates.
- Fasentra-renewal PA criteria would look at eosinophil count reduction to show effectiveness; advantage of physician administered drug-know patient is getting medication; Dupixent-not small volume being administered, but benefit seen right away.
- Zemdri-the more broader new antibiotics are used the more quicker resistance develops, so use should be reserved as conservative as possible; possible outpatient use in patients that have PIC lines; culture and sensitivity showing resistance to preferred aminoglycosides is reasonable.

**DCH Decisions**

DCH Decisions from the November 2018 DUR Board meeting were provided in the DCH Decision section of the DUR Board binder.

**Upcoming Meetings**

The following upcoming meetings were published in the DURB binder:

- Drug Utilization Review Board  
2 Peachtree Street NW  
5<sup>th</sup> Floor Board Room  
Atlanta, Georgia 30303

Thursday, May 2, 2019

Tuesday, August 6, 2019

Tuesday, November 5, 2019

**Disclosure Forms**

Disclosure forms were received and reviewed by the Department for completeness for all Board members attending the meeting.

**Adjournment of Open Session**

The DUR Board voted to close the open meeting pursuant to the Open Meeting Act of Georgia Section 50-14-1 – 50-14-6 and pursuant to Federal Law Section 1396R-8B3D. The individuals recorded in attendance with the Board members were from the Department of Community Health, Magellan Rx Management, NorthStar HealthCare Consulting, and OptumRx. CMO representatives, Turkesia Robertson-Jones, Pharm.D. (CareSource), Charles Kim, Pharm.D., (PeachState), and pharmacy students Sarah Pickering (UGA), Raiford Ready (UGA), Kelsey Adams (UGA), and Cody Collins (PCOM), also attended the closed session with Board members. A motion was made by Danny A. Toth, R.Ph., and seconded by Robyn Lorys, Pharm.D., to adjourn the open session and approve the closed session. There was a unanimous vote approving the closed session. The Chairman, Burton L. Lesnick, M.D., FAAP, adjourned

**Department of Community Health  
Drug Utilization Review Board (DURB)  
MINUTES**

**Tuesday, March 5, 2019**

the open session at approximately 11:38am, at which time members took a break then reconvened for the executive (closed) session.

**Student Introductions**

The following students were introduced: Sarah Pickering (UGA), Raiford Ready (UGA), Kelsey Adams (UGA), and Cody Collins (PCOM).

**Executive Session**

The Executive Session was held from 11:48am to 12:42pm.

**Reconvening of Open Session**

The DUR Board reconvened for the open session at 12:45pm.

**Board's Recommendations to the Department**

After all clinical and financial evaluations and discussions, the DUR Board voted and presented the Department with the following recommendations for changes to the Preferred Drug List (PDL) as noted in Attachment A. All motions and votes are noted in Attachment B.

**Future Agenda Items**

There were no future agenda items noted.

**Conclusion**

At the conclusion of the reconvened open session and no other business for discussion, there was a unanimous decision to adjourn the meeting. Chair Lesnick adjourned the meeting at 12:50pm.

THESE MINUTES ARE HEREBY APPROVED AND ADOPTED, THIS THE \_\_\_\_\_  
DAY OF \_\_\_\_\_, 2019.

---

Burton L. Lesnick, M.D., FAAP, Chair



The Drug Utilization Review (DUR) Board Reviewed  
the Following New Drugs/Classes on  
March 5, 2019

<b>Therapeutic Class</b>	<b>Drug Name</b>	<b>DURB Recommendations</b>
<b>Immunomodulators, Asthma</b>		
	<i>Fasenra (Subcutaneous) Injection</i>	Defer to future meeting
<b>Potassium Binders</b>		
	<i>Lokelma (Oral) Powder for Suspension</i>	NP/PA
<b>Opiate Dependence Treatments</b>		
	<i>Lucemyra (Oral) Tablets</i>	NP/PA
<b>Uterine Disorder Treatments</b>		
	<i>Orilissa (Oral) Tablets</i>	P/PA
<b>Antibiotics, Vaginal</b>		
	<i>Solosec (Oral) Granules</i>	NP/PA
<b>Aminoglycosides</b>		
	<i>Zemdri (Intravenous) Injection</i>	P/PA (for coverage on the PADL)

DURB=Drug Utilization Review Board; P=preferred; NP=non-preferred; PA=prior authorization;  
PADL=Providers' Administered Drug List

*This page intentionally left blank*

# Drug Utilization Review Board

Motions - Votes - **New Drugs**

**March 5, 2019**

New Drug	Drug	PDL Status	Motion - Recommendations	Additional Comments	
<b>Immunomodulators, Asthma</b>	Fasenra (Subcutaneous) Injection	N/A	Defer to May Meeting	Due to no utilization criteria	
<b>Board Members - Present</b>	Motion Maker (v)	Seconded By (v)	<b>VOTES</b>		
(Strike out, when absent)			YES (v)	NO (v)	ABSTAIN (v)
1 Avery, Mia, Pharm.D.			√		
2 Condra III, Alton, R.Ph.			√		
3 Doad, Gurinder J.S., M.D.-			√		
4 Fowler, M. Celeste, Pharm.D. - <b>Vice</b>			√		
5 Lesnick, Burton, M.D. - <b>Chair</b>			√		
7 Lorys, Robyn Pharm.D.		√	√		
6 May, J. Russell (Rusty)			√		
8 Miller,Osgood (Drew) A., R.Ph.			√		
9 Perri, Matthew, R.Ph., Ph.D.	√		√		
10 Rollins, Brent L., R.Ph., Ph.D.			√		
11 Toth, Danny, R.Ph.			√		
<b>TOTAL</b>			<b>11</b>	<b>0</b>	<b>0</b>
<b>Board Members - Absent</b>					
1 Collins, Douglas, M.D.					
2 Duraski, Rod, M.D.					
3 Gordon, Glenda Wrenn, M.D.					

# Drug Utilization Review Board

Motions - Votes - **New Drugs**

**March 5, 2019**

New Drug	Drug	PDL Status	Motion - Recommendations	Additional Comments	
<b>Potassium Binders</b>	Lokelma (Oral) Powder for Suspension	N/A	NP/PA		
<b>Board Members - Present</b> <small>(Strike out, when absent)</small>	<b>Motion Maker (v)</b>	<b>Seconded By (v)</b>	<b>VOTES</b>		
			<b>YES (v)</b>	<b>NO (v)</b>	<b>ABSTAIN (v)</b>
1 Avery, Mia, Pharm.D.		√	√		
2 Condra III, Alton, R.Ph.			√		
3 Doad, Gurinder J.S., M.D.-	√		√		
4 Fowler, M. Celeste, Pharm.D. - <b>Vice</b>			√		
5 Lesnick, Burton, M.D. - <b>Chair</b>			√		
7 Lorys, Robyn Pharm.D.			√		
6 May, J. Russell (Rusty)			√		
8 Miller,Osgood (Drew) A., R.Ph.			√		
9 Perri, Matthew, R.Ph., Ph.D.			√		
10 Rollins, Brent L., R.Ph., Ph.D.			√		
11 Toth, Danny, R.Ph.			√		
<b>TOTAL</b>			<b>11</b>	<b>0</b>	<b>0</b>
<b>Board Members - Absent</b>					
1 Collins, Douglas, M.D.					
2 Duraski, Rod, M.D.					
3 Gordon, Glenda Wrenn, M.D.					

# Drug Utilization Review Board

Motions - Votes - **New Drugs**

**March 5, 2019**

<b>New Drug</b>	<b>Drug</b>	<b>PDL Status</b>	<b>Motion - Recommendations</b>	<b>Additional Comments</b>	
<b>Opiate Dependence Treatments</b>	<b>Lucemyra (Oral) Tablets</b>	N/A	<b>NP/PA</b>	Outpatient use limited to continuation of inpatient use only	
<b>Board Members - Present</b>	<b>Motion Maker (v)</b>	<b>N/A Seconded By (v)</b>	<b>VOTES</b>		
<u>(Strike out, when absent)</u>			<b>YES (v)</b>	<b>NO (v)</b>	<b>ABSTAIN (v)</b>
1 Avery, Mia, Pharm.D.			√		
2 Condra III, Alton, R.Ph.			√		
3 Doad, Gurinder J.S., M.D.-			√		
4 Fowler, M. Celeste, Pharm.D. - <b>Vice</b>			√		
5 Lesnick, Burton, M.D. - <b>Chair</b>			√		
7 Lorys, Robyn Pharm.D.			√		
6 May, J. Russell (Rusty)	√		√		
8 Miller,Osgood (Drew) A., R.Ph.		√	√		
9 Perri, Matthew, R.Ph., Ph.D.			√		
10 Rollins, Brent L., R.Ph., Ph.D.			√		
11 Toth, Danny, R.Ph.			√		
<b>TOTAL</b>			<b>11</b>	<b>0</b>	<b>0</b>
<b>Board Members - Absent</b>					
1 Collins, Douglas, M.D.					
2 Duraski, Rod, M.D.					
3 Gordon, Glenda Wrenn, M.D.					

# Drug Utilization Review Board

Motions - Votes - **New Drugs**

**March 5, 2019**

New Drug	Drug	PDL Status	Motion - Recommendations	Additional Comments	
<b>Uterine Disorder Treatments</b>	Orilissa (Oral) Tablets	N/A	P/PA		
<b>Board Members - Present</b>	<b>Motion Maker (v)</b>	<b>Seconded By (v)</b>	<b>VOTES</b>		
<small>(Strike out, when absent)</small>			<b>YES (v)</b>	<b>NO (v)</b>	<b>ABSTAIN (v)</b>
1 Avery, Mia, Pharm.D.	√		√		
2 Condra III, Alton, R.Ph.			√		
3 Doad, Gurinder J.S., M.D.-			√		
4 Fowler, M. Celeste, Pharm.D. - <b>Vice</b>			√		
5 Lesnick, Burton, M.D. - <b>Chair</b>			√		
7 Lorys, Robyn Pharm.D.			√		
6 May, J. Russell (Rusty)			√		
8 Miller,Osgood (Drew) A., R.Ph.			√		
9 Perri, Matthew, R.Ph., Ph.D.			√		
10 Rollins, Brent L., R.Ph., Ph.D.		√	√		
11 Toth, Danny, R.Ph.			√		
<b>TOTAL</b>			<b>11</b>	<b>0</b>	<b>0</b>
<b>Board Members - Absent</b>					
1 Collins, Douglas, M.D.					
2 Duraski, Rod, M.D.					
3 Gordon, Glenda Wrenn, M.D.					

# Drug Utilization Review Board

Motions - Votes - **New Drugs**

**March 5, 2019**

New Drug	Drug	PDL Status	Motion - Recommendations	Additional Comments	
<b>Antibiotics, Vaginal</b>	<b>Solosec (Oral) Granules</b>	N/A	<b>NP/PA</b>	Step through requirements for metronidazole and clindamycin	
<b>Board Members - Present</b>	<b>Motion Maker (v)</b>	<b>N/A Seconded By (v)</b>	<b>VOTES</b>		
<b>(Strike out, when absent)</b>			<b>YES (v)</b>	<b>NO (v)</b>	<b>ABSTAIN (v)</b>
1 Avery, Mia, Pharm.D.			√		
2 Condra III, Alton, R.Ph.			√		
3 Doad, Gurinder J.S., M.D.-			√		
4 Fowler, M. Celeste, Pharm.D. - <b>Vice</b>			√		
5 Lesnick, Burton, M.D. - <b>Chair</b>			√		
7 Lorys, Robyn Pharm.D.	√		√		
6 May, J. Russell (Rusty)			√		
8 Miller, Osgood (Drew) A., R.Ph.			√		
9 Perri, Matthew, R.Ph., Ph.D.			√		
10 Rollins, Brent L., R.Ph., Ph.D.			√		
11 Toth, Danny, R.Ph.		√	√		
<b>TOTAL</b>			<b>11</b>	<b>0</b>	<b>0</b>
<b>Board Members - Absent</b>					
1 Collins, Douglas, M.D.					
2 Duraski, Rod, M.D.					
3 Gordon, Glenda Wrenn, M.D.					

# Drug Utilization Review Board

Motions - Votes - **New Drugs**

**March 5, 2019**

	Drug	PDL Status	Motion - Recommendations	Additional Comments	
<b>New Drug</b>					
<b>Aminoglycosides</b>				For Coverage on the Provider Administered Drug List (PADL)	
<b>Board Members - Present</b> <i>(Strike out, when absent)</i>	<b>Zemdri (Intravenous) Injection</b>	N/A	<b>P/PA</b>	<b>VOTES</b>	
	<b>Motion Maker (v)</b>	<b>Seconded By (v)</b>	<b>YES (v)</b>	<b>NO (v)</b>	<b>ABSTAIN (v)</b>
1 Avery, Mia, Pharm.D.			√		
2 Condra III, Alton, R.Ph.			√		
3 Doad, Gurinder J.S., M.D.-			√		
4 Fowler, M. Celeste, Pharm.D. - <b>Vice</b>			√		
5 Lesnick, Burton, M.D. - <b>Chair</b>			√		
7 Lorys, Robyn Pharm.D.			√		
6 May, J. Russell (Rusty)			√		
8 Miller,Osgood (Drew) A., R.Ph.	√		√		
9 Perri, Matthew, R.Ph., Ph.D.			√		
10 Rollins, Brent L., R.Ph., Ph.D.			√		
11 Toth, Danny, R.Ph.		√	√		
<b>TOTAL</b>			<b>11</b>	<b>0</b>	<b>0</b>
<b>Board Members - Absent</b>					
1 Collins, Douglas, M.D.					
2 Duraski, Rod, M.D.					
3 Gordon, Glenda Wrenn, M.D.					

## Important Update DCH Decision Document

### Listed below are Preferred Drug List changes for the State of Georgia Fee-For-Service Medicaid and PeachCare for Kids Programs

Effective April 1, 2019 (see chart below)

DCH rebate vendor Magellan Medicaid Administration (MMA) has reviewed SFY2019 supplemental rebate offers with DCH and also reviewed specific drug categories at the March 2019 DURB meeting. The PDL/PADL decisions or PDL/PADL changes for new drugs or categories reviewed during the March DURB meeting are outlined below. **Those drugs highlighted in red indicate a change from current PDL status.** For a full listing of our PDL, go to [www.dch.georgia.gov/pharmacy](http://www.dch.georgia.gov/pharmacy) and select the “preferred product list” option.

PREFERRED AGENTS	NON-PREFERRED AGENTS
<b>ONLY DRUGS reviewed during the March 2019 DURB meeting as either new to market or a change in PDL status are listed</b>	
<b>AMINOGLYCOSIDES</b>	
ZEMDRI (PADL only)*	
<b>ANTIBIOTICS, VAGINAL</b>	
	SOLOSEC
<b>OPIATE DEPENDENCE TREATMENTS</b>	
	LUCEMYRA
<b>POTASSIUM BINDERS</b>	
	LOKELMA
<b>UTERINE DISORDER TREATMENTS</b>	
ORILISSA	

\*effective 7/1/2019

*This page intentionally left blank*

**Georgia Department of Community Health (GDCH)  
Opportunities for Pharmaceutical Manufacturer Input on Clinical  
Recommendations and Clinical Management Strategies by the  
Drug Utilization Review Board**

Clinical Information and Clinical Management Strategies relevant to the GDCH Medicaid Fee-For-Service program will be presented to the Drug Utilization Review Board (DURB) at each meeting through OptumRx by its vendor NorthStar HealthCare Consulting (NHC). Manufacturer input on new and existing drugs is welcomed and appreciated using these opportunities. **Please note that new drug entities are generally not reviewed by the DURB until the drug has been on the market for at least 6 months.**

**Ongoing Opportunity:**

**DUR Board Meeting Process:** Drugs, therapeutic classes and/or supplemental rebate classes under review will be posted to the DCH website at <http://dch.georgia.gov/durb-meeting-information> approximately 30 days prior to the Manufacturers' Forum. Input specific to the drugs under review from manufacturers are made directly to NHC via [GAMedicaid@nhc-llc.com](mailto:GAMedicaid@nhc-llc.com) and reported as appropriate by NHC at subsequent DURB meetings. NHC will pass relevant manufacturer-submitted electronic materials to the DURB members via a secure FTP site.

Upon review of information, and based on its expertise and discussions, the DURB makes recommendations to GDCH.

**Opportunity to Appeal to GDCH:**

**GDCH Review Process:** DURB recommendations are reviewed by GDCH for final decisions. Manufacturers may request an appeal meeting directly with GDCH after conclusion of each quarterly DURB meeting and **this appeal meeting must be conducted within 10 business days following the DURB meeting.** **Contact: Shirmary Hodges at (404) 656-4044 or [shodges@dch.ga.gov](mailto:shodges@dch.ga.gov)**

**Presentation Opportunity:**

**Manufacturers' Forum:** A forum prior to each relevant DURB meeting whereby manufacturers may present:

- 1) Clinical information relevant to a new drug on the market or a drug that is part of a therapeutic or supplemental rebate class under review by the DURB at the next meeting.
- 2) Clinical information relevant to ongoing NHC/OptumRx clinical management strategies (e.g. review of drug benefit plan designs, new drugs coming to market, new indications, etc.) as deemed necessary by NHC/OptumRx.

Please see the Manufacturers' Forum Announcement at <http://dch.georgia.gov/durb-meeting-information>.

**Questions not addressed in this document may be sent to NorthStar  
HealthCare Consulting by e-mail: [GAMedicaid@nhc-llc.com](mailto:GAMedicaid@nhc-llc.com)**

*This page intentionally left blank*

**2019**

## **Upcoming Meetings**

### **Drug Utilization Review Board Meeting**

2 Peachtree Street, N.W.

5<sup>th</sup> Floor Board Room

Atlanta, Georgia 30303

Tuesday, March 5, 2019: 10:00am – 2:00pm

Tuesday, May 7, 2019: 10:00am – 3:00pm

Tuesday, August 6, 2019: TBD

Tuesday, November 5, 2019: TBD

*This page intentionally left blank*

### Drug Utilization Review Board

<b>Board Member</b>	<b>Credentials</b>	<b>Specialty/Area of Expertise</b>	<b>Company Name</b>
<b>Burton L. Lesnick, Chair</b>	M.D., FAAP	Pediatrics/Pediatric Pulmonology	Children's Healthcare of Atlanta
<b>M. Celeste Fowler, Vice-Chair</b>	Pharm.D., HCMBA	340B Pharmacy	Piedmont Henry Hospital
<b>Mia Avery</b>	Pharm.D.	Oncology Pharmacy	Emory University Hospital Winship Cancer Institute
<b>Douglas C. Collins</b>	M.D.	Hematology/Oncology	Metro Hematology-Oncology, PC
<b>Alton Condra III</b>	R.Ph.	HIV/AIDS Pharmacy - Infectious Disease Program	Grady Memorial Hospital
<b>Gurinder J.S. Doad</b>	M.D., Ph.D.	Family Practice	Southwest Georgia Family Medicine and Mercer University School of Medicine
<b>Rod M. Duraski</b>	M.D., FACP, MBA	Internal Medicine	West Georgia Health
<b>Glenda Gordon</b>	M.D.	Psychiatry, Academia - Professor	Morehouse School of Medicine
<b>Robyn Lorys</b>	Pharm.D.	Academia - Professor	Mercer University College of Pharmacy
<b>J. Russell May</b>	Pharm.D.	Academia - Professor	University of Georgia College of Pharmacy
<b>Drew A. Miller</b>	R.Ph.	Retail Pharmacy	Wynn's Pharmacy
<b>Matthew Perri III</b>	Ph.D., R.Ph.	Academia - Professor	University of Georgia College of Pharmacy
<b>Brent L. Rollins</b>	R.Ph., Ph.D.	Academia - Professor	Philadelphia College of Osteopathic Medicine School of Pharmacy
<b>Danny A. Toth</b>	R.Ph.	Pharmacy Benefit Plans	Timber Ridge Consultants, LLC